Viral Infections
RSSArticles
Being Mindful of COVID’s Effects on Cognitive Decline
A large observational study finds objective evidence of lingering cognitive deficits associated with past COVID-19 infection, particularly in patients infected early in the pandemic, those hospitalized, or those with prolonged illness duration.
Respiratory Syncytial Virus or Influenza in Older Patients: Which Is Worse?
In individuals 75 years of age or older, respiratory syncytial virus infection was associated with more severe illness than was influenza virus infection.
Avian Influenza A(H5N1) — From Birds to Cows to Human Infection
The spread of influenza H5N1 in dairy cows with documentation of a human infection raises pandemic concern.
Respiratory Syncytial Virus or Influenza in Older Patients: Which Is Worse?
In individuals 75 years of age or older, respiratory syncytial virus infection was associated with more severe illness than was influenza virus infection.
Nirmatrelvir-Ritonavir in High-Risk Vaccinated and Low-Risk Unvaccinated Participants: The EPIC-SR Trial
In this Phase II-III randomized controlled clinical trial (EPIC-SR), nirmatrelvir-ritonavir was not associated with a significant difference in time to alleviation of symptoms nor COVID-19-related hospitalization or death from any cause as compared with placebo in unvaccinated individuals without risk factors for severe disease or in vaccinated individuals with a least one risk factor for severe disease.
Predicting Outcomes of Congenital Cytomegalovirus Infection
Congenital cytomegalovirus infection can cause hearing loss and neurologic deficits, but most affected newborns escape without sequelae. New data suggest a good prognosis if the mother’s infection was after the first trimester and if the newborn has normal hearing, a normal platelet count, and a normal head ultrasound exam.
Vaccine Effectiveness Against Long COVID in Children and Adolescents
Findings consistent with long COVID occur in 4.5% of infected children. COVID vaccination reduces the risk of long COVID by 50% in adolescents and by 24% in children aged 5 to 11 years.
Molnupiravir vs. Nirmatrelvir-Ritonavir for Early Symptomatic COVID-19
A randomized, controlled, multicenter Phase II clinical trial compared molnupiravir, ritonavir-boosted nirmatrelvir, or no drug for low-risk adult patients ages 18-50 years with symptomatic COVID-19. Viral clearance was 84% faster with ritonavir-boosted nirmatrelvir and 37% faster with molnupiravir compared to no treatment.
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
CDC Recommends RSV Vaccine for Patients in Third Trimester
The agency says this solution should be administered to patients during weeks 32 through 36 of pregnancy to protect babies against the dangerous virus, both before and shortly after birth.